A characterization study of resveratrol/sulfobutyl ether-β-cyclodextrin inclusion complex and in vitro anticancer activity

被引：113

作者：

Venuti, Valentina ^{[1
]}

Cannava, Carmela ^{[2
]}

Cristiano, Maria Chiara ^{[3
]}

Fresta, Massimo ^{[3
]}

Majolino, Domenico ^{[1
]}

Paolino, Donatella ^{[3
]}

Stancanelli, Rosanna ^{[2
]}

Tommasini, Silvana ^{[2
]}

Ventura, Cinzia Anna ^{[2
]}

机构：

[1] Univ Messina, Dipartimento Fis & Sci Terra, I-98166 Messina, Italy

[2] Univ Messina, Dipartimento Sci Farmaco & Prodotti Salute, I-98168 Messina, Italy

[3] Magna Graecia Univ Catanzaro, Dipartimento Sci Salute, I-88100 Catanzaro, Italy

来源：

COLLOIDS AND SURFACES B-BIOINTERFACES | 2014年 / 115卷

关键词：

Resveratrol; Sulfobutylether-beta-cyclodextrin; FTIR-ATR; Job's plot; Anticancer activity; KAPPA-B ACTIVATION; FTIR-ATR; PHYSICOCHEMICAL CHARACTERIZATION; VIBRATIONAL PROPERTIES; SOLUBILITY;

D O I：

10.1016/j.colsurfb.2013.11.025

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

A resveratrol/sulfobutylether-beta-cyclodextrin inclusion complex was prepared using the freeze-drying method and characterized in solution through UV-vis spectroscopy, solubility phase studies and Job's plot methods. At the solid state it was characterized using the FTIR-ATR technique. Sulfobutylether-beta-cyclodextrin has a high affinity for the drug, and forms an inclusion complex with a 1:1 molar ratio both in solution and as a solid sample. It also has a high stability constant (K-c, 10,114M(-1)). Complexation strongly increases the water solubility of resveratrol (from 0.03 mg/ml to 1.1 mg/ml, at 25 degrees C) and positively influences its in vitro anticancer activity which was observed on a human breast cancer cell line (MCF-7). In solid phase, FTIR-ATR revealed itself as being a useful technique in elucidating the complexation mechanism, which it did by emphasizing the functional groups involved in the activation of non-covalent "host-guest" interactions. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：22 / 28

页数：7

共 41 条

[1] Synthesis and characterization of the inclusion complex between repaglinide and sulfobutylether-β-cyclodextrin (Captisol®) [J].